drugset / Trial / NCT03645824
Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)
Phase 2
Active not recruiting
61 enrolled
HOVON Foundation
CTI BioPharma · collabDutch Cancer Society · collab
NaSingle-groupOpen-labelTreatment
Summary
The only curative treatment for patients with myelofibrosis (MF) is allogeneic stem cell transplantation (SCT). Treatment with JAK2 inhibitors like pacritinib improves condition of MF patients, decreases spleen size and might diminish graft-versus-host disease (GvHD), thereby improving the outcome of SCT.
Timeline
- Start
- 2018-06-04
- Primary completion
- 2023-07
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pacritinib | Small molecule | — | — |